Michelle Gayari

Michelle Gayari, Executive Vice President, Global Operational Excellence and Innovation and member of the Executive Team at MMS, leads the global technical, medical and scientific functions. She has more than 20 years of experience in clinical research, including career highlights at the Mayo Clinic and Pfizer, prior to joining MMS.

Michelle’s long tenure in the data service area and commitment to excellence, fosters a culture across our global offices that attracts the best talent. Her global operational teams are responsible for all elements of clinical trial data strategies and tech-enabled services, including specialized expertise in all data and summarization steps leading to successful NDA submissions globally. Michelle established a Center of Excellence within the global operational teams that bring value beyond the deliverable, emphasizing strong science and process. Metrics and a strong emphasis on service delivery methodology drive the organization. Her teams lend their expertise to client sponsors ensuring the highest level of customer satisfaction and return on their investment.

The growth that MMS has experienced since day one is truly due to the people in our offices across the world. We’ve been able to not only develop highly talented professionals but we play a critical role in the process of bringing life altering drugs to market. I like to say that “good work rises to the top,” and I am continually reminded of that every day.
Michelle Gayari
Executive Vice President, Global Operational Excellence and Innovation

She earned her BS in Statistics, Mathematics, and Psychology from Central Michigan University. Michelle’s commitment to mentoring and education extends to the community, including a board position on T.E.A.C.H. and continued expansion of MMS Academy curriculum.

Suggested For You

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award 

perspectives

May 28th, 2025

A Season of Change: Why the REMS Industry Consortium Matters More Than Ever

perspectives

May 20th, 2025

Navigating FDA OMOR Meetings: A Comprehensive Guide to Type X, Y, and Z Meetings for OTC Drug Sponsors

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success